top of page

Frequency Therapeutics is aiming to correct hearing loss by using small molecules to reactivate prog

  • Jan 18, 2017
  • 1 min read

NOW HEAR THIS By Lauren Martz, Senior Writer Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next generation approach to regenerative medicine that uses small molecules to reactivate a patient’s dormant progenitor cells in vivo. The newco emerged from stealth mode last week with the announcement of its new board of directors, which is headed by Chairman Marc Cohen, co-founder of Cobro Ventures, and includes serial entrepreneur and co-founder Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology. The company has an undisclosed amount of financing from Cobro, and a group of angel and super angel investors. Continue reading ... pdf

 
 
 

Comments


Featured Posts
Recent Posts
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • LinkedIn Social Icon

© 2024 by

C2I Accelerator Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@c2ixcel.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | C2I | Life Science | Lease Lab Space | Biotech

bottom of page